Quantcast

Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update - Live5News.com | Charleston, SC | News, Weather, Sports

Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Avanir Pharmaceuticals, Inc.

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2014.

Quarterly Financial Highlights

  • Total company net revenues of $28.6 million.
  • Net NUEDEXTA® sales of $26.5 million.
  • Cash, cash equivalents, and restricted investments of $87.6 million as of June 30, 2014.

"We had a great quarter across all aspects of our business. I am delighted with the positive outcome of our ANDA patent litigation, solid revenue growth of 45% year-over-year, and the positive interim data from our open label PRISM II study in PBA and COMPASS clinical trial in migraine," said Keith A. Katkin, president and CEO of Avanir. "The future looks very promising as we are in the midst of expanding the sales force which should further accelerate revenue growth and we will announce data from our agitation and levodopa-induced dyskinesia trials later this year."

Fiscal 2014 Third Quarter Results

  • Total net revenues for the third quarter fiscal 2014 were $28.6 million, compared with $19.8 million for the comparable quarter in fiscal 2013, representing 45 percent year-over-year growth. Total net revenues consist of NUEDEXTA revenue, Abreva® royalties and co-promotion revenues.
  • Total operating expenses were $40.5 million in the third quarter of fiscal 2014, compared with $30.2 million in the comparable period in fiscal 2013.
  • Cash used in operations was $16.1 million in the third quarter of fiscal 2014.
  • Net loss for the fiscal 2014 third quarter was $12.7 million, or $0.08 per share, compared with a net loss of $11.4 million, or $0.08 per share, for the same period in fiscal 2013.

Fiscal 2014 Nine-Month Results

  • Total net revenues for the first nine months of fiscal 2014 totaled $82.3 million, compared with $53.7 million for the first nine months of fiscal 2013.
  • Total operating expenses were $116.0 million in the first nine months of fiscal 2014, compared to $90.6 million in the comparable period for fiscal 2013.
  • Cash used in operations was $41.6 million in the first nine months of fiscal 2014.
  • Net loss for the first nine months of fiscal 2014 was $36.3 million, or $0.23 per share, compared with a net loss of $40.0 million, or $0.29 per share, for the comparable period in fiscal 2013.

Cash, Cash Equivalents & Marketable Securities

As of June 30, 2014 Avanir had cash, cash equivalents and investments in securities totaling $87.6 million, including cash and cash equivalents of $85.0 million.

Quarter and Recent Business Highlights

  • Prevailed in NUEDEXTA patent litigation resulting in maintaining exclusivity through July 2026.
  • Completed patient enrollment for the company's phase II, placebo-controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients. The company expects to have top-line results from this study in late September/early October.
  • Presented research findings from the company's central nervous system therapeutic franchise at the American Academy of Neurology meeting, the Alzheimer's Association International Conference, and the Joint Congress of European Neurology.
  • Announced positive data from the phase IIIb COMPASS trial: A head-to-head study comparing AVP-825 to oral sumatriptan for the acute treatment of migraine. The data show that migraine sufferers achieved greater rates of pain relief and pain freedom within 30 minutes with AVP-825 treatment compared with oral sumatriptan treatment.
  • Presented positive interim PRISM II data showing that NUEDEXTA provided meaningful reduction of pseudobulbar affect (PBA) episodes and is generally well tolerated in the Alzheimer's disease/dementia population.
  • Announced FDA acceptance of the investigational new drug (IND) application for AVP-786 for the adjunctive treatment of major depressive disorder and that the company plans to initiate a 200 patient phase II clinical trial during the third calendar quarter of 2014.
  • Completed expansion of institutional sales force, doubling the total size to 160 representatives, enabling the organization to extend its reach and frequency. Additionally, the company initiated the expansion of its retail sales force to add 70 additional representatives to further accelerate growth of NUEDEXTA in the out-patient setting.

Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2014 third quarter financial results today, August 5, 2014, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1 (877) 474-9503 for domestic callers or +1 (857) 244-7556 for international callers, and entering passcode 33730262. Those interested in listening to the conference call live via the internet may do so by visiting http://ir.avanir.com.

About AVP-825

AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath Powered delivery technology. If approved, AVP-825 would be the first and only fast-acting, dry-powder intranasal form of sumatriptan for the treatment of migraine. AVP-825 is an investigational drug-device combination product not approved by the FDA. In the phase III clinical trial the most common AEs (incidence >5%) reported for AVP-825 were product taste (22%), nasal discomfort (13%), and rhinitis (6%); local AEs were almost exclusively mild to moderate in severity and transient. Sumatriptan is contraindicated for certain patients, including those with a history of coronary artery disease (CAD) or coronary vasospasm.

About AVP-786

AVP-786 is a novel investigational drug product consisting of a combination of deuterium modified dextromethorphan (an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter) and ultra-low dose quinidine (a CYP2D6 enzyme inhibitor). Incorporation of deuterium into specific positions of the dextromethorphan molecule strengthens the chemical bonds and reduces susceptibility to enzyme cleavage and first pass metabolism, but without altering its pharmacology. AVP-786 is an investigational drug not approved by the FDA.

About AVP-923

AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. AVP-923 is being studied in several ongoing company sponsored Phase II clinical trials including agitation in Alzheimer's disease, levodopa-induced dyskinesia in Parkinson's disease, and multiple investigator initiated studies. AVP-923 is an investigational drug not approved by the FDA. AVP-923 at the 20/10 mg dose strength is approved by the FDA for the treatment of pseudobulbar affect (PBA) and marketed under the trade name NUEDEXTA (see description below). AVP-923 is an investigational drug not approved by the FDA for any uses other than PBA.

About NUEDEXTA

NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA Important Safety Information

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.

NUEDEXTA and certain other medicines can interact, causing serious side effects. If you take certain drugs or have certain heart problems, NUEDEXTA may not be right for you.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness.

These are not all the risks from use of NUEDEXTA. Please refer to full Prescribing Information at www.NUEDEXTA.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining additional indications, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700


AVANIR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS






June 30,


September 30,


2014


2013


(unaudited)


(audited)

ASSETS

Current assets:




     Cash and cash equivalents

$   84,972,477


$    55,259,073

     Restricted cash and cash equivalents

1,319,030


965,986

     Trade receivables, net

21,363,961


12,525,992

     Inventories, net

685,785


710,179

     Prepaid expenses and other current assets

4,252,331


2,382,410

          Total current assets

112,593,584


71,843,640

Restricted long-term investments

1,304,065


1,303,938

Property and equipment, net

3,184,206


1,592,791

Non-current inventories, net

692,918


784,186

Other assets

670,641


554,452

       TOTAL ASSETS

$ 118,445,414


$    76,079,007





LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:




    Accounts payable, accrued expenses and other liabilities

$   25,391,001


$    25,560,756

    Current portion of note payble

11,455,155


7,942,945

    Current portion of deferred royalty revenues

-


1,288,514

       Total current liabilities

36,846,156


34,792,215

Accrued expenses and other liabilities, net of current portion

2,164,583


1,393,075

Note Payable

12,719,252


21,422,163

        Total liabilities

51,729,991


57,607,453

         Total stockholders' equity

66,715,423


18,471,554

TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY

$ 118,445,414


$    76,079,007









AVANIR PHARMACEUTICALS, INC.

CONDENSED STATEMENT OF OPERATIONS



Three Months Ended June 30,


Nine Months Ended June 30,


2014


2013


2014


2013

REVENUES








   Net product sales

$  26,540,131


$  19,044,288


74,218,317


50,458,609

   Revenues from royalties

178,786


714,374


2,743,381


3,239,513

   Revenue from co-promotion with Merck

1,801,925


-


5,252,267


-

   Revenue from research grant services

110,000


-


110,000


15,000

           Total revenues

28,630,842


19,758,662


82,323,965


53,713,122









OPERATING EXPENSES








   Cost of product sales

1,491,319


1,077,736


4,153,731


2,849,291

   Cost of research grant services

198,039


-


198,039


78,488

   Research and development

12,300,483


6,053,684


31,718,059


21,576,073

   Selling and marketing

19,023,444


16,005,750


55,403,092


45,589,577

   General and administrative

7,509,872


7,031,615


24,515,143


20,548,702

           Total operating expenses

40,523,157


30,168,785


115,988,064


90,642,131









Loss from operations

(11,892,315)


(10,410,123)


(33,664,099)


(36,929,009)









OTHER INCOME (EXPENSE)








   Interest income

5,334


10,183


14,873


44,579

   Interest expense

(811,782)


(1,024,462)


(2,664,993)


(3,142,952)

   Other, net

-


(228)


(8,837)


(31)









Loss before provision for income taxes

(12,698,763)


(11,424,630)


(36,323,056)


(40,027,413)









   Provision for income taxes
















Net loss and comprehensive loss

$ (12,698,763)


$ (11,424,630)


$ (36,323,056)


$ (40,027,413)









Basic and diluted net loss per share

$            (0.08)


$            (0.08)


$            (0.23)


$            (0.29)









Basic and diluted weighted average number of common shares outstanding 

166,016,719


145,244,796


157,574,373


140,388,237

























 

Avanir Pharmaceuticals, Inc.

Logo - http://photos.prnewswire.com/prnh/20130207/LA55901LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow